4,451 results match your criteria rituximab combination

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.

Front Pharmacol 2021 19;12:644187. Epub 2021 Apr 19.

Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.

Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-quality care. Belgium is a country known to have low biosimilar market shares, suggesting a malfunctioning market for off-patent biologicals. This study aims to gain an in-depth understanding of the Belgian off-patent biologicals market, by looking at the evolution in volumes and costs of the relevant products in the market. Read More

View Article and Full-Text PDF

Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent.

Rheumatol Ther 2021 May 3. Epub 2021 May 3.

Sorbonne University, Assistance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.

Introduction: Rheumatoid arthritis (RA) clinical guidelines do not provide strong recommendations for the choice of disease-modifying anti-rheumatic drugs (DMARD) in patients with an inadequate response to methotrexate (MTX), and only limited evidence is available on factors influencing rheumatologist treatment decisions. We aimed to describe therapeutic preferences after the failure of a first-line strategy of MTX in simulated cases of patients with RA.

Methods: Fictional but realistic case-vignettes (n = 64) of patients with RA and an inadequate response to MTX were developed with a combination of RA-poor prognostic factors and comorbidities. Read More

View Article and Full-Text PDF

Eltrombopag Dose Adjustment During Infection-Induced Thrombocytosis in a Patient With Chronic Idiopathic Thrombocytopenic Purpura.

Cureus 2021 Mar 29;13(3):e14166. Epub 2021 Mar 29.

Hematology and Oncology, Hamad General Hospital, Doha, QAT.

Idiopathic thrombocytopenic purpura (ITP) is an immune disorder in which antibodies attack platelets, leading to platelet destruction and increased bleeding risk. Standard treatment is to maintain a platelet count sufficient to mitigate the bleeding risk. First-line therapies include steroids and IV immunoglobulins, and second-line therapy includes thrombopoietin receptor agonists like eltrombopag in combination with other medications (e. Read More

View Article and Full-Text PDF

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.

Jun Ho Yi

Blood Res 2021 Apr;56(S1):S1-S4

Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.

Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. Read More

View Article and Full-Text PDF

Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.

Biochem Pharmacol 2021 Apr 27:114576. Epub 2021 Apr 27.

Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China; School of Medicine, Shandong University, Jinan, Shandong, 250012, China; Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou 251006, China. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) with high clinical heterogeneity and poor prognosis. Immune escape mediated by CD47 overexpression contributes to the limited efficacy of rituximab, an anti-CD20 antibody, which indicates a target to improve the efficacy of DLBCL treatment. Here, we validated berberine, a natural compound, as a suppressor of CD47 and revealed the involved mechanism and biological function in DLBCL. Read More

View Article and Full-Text PDF

A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.

N Z Med J 2021 Apr 16;134(1533):33-45. Epub 2021 Apr 16.

Regional Cancer Treatment Service, MidCentral District Health Board.

Background: Chemotherapy-induced nausea and vomiting (CINV) are two of the most frequently experienced and distressing side effects of cancer treatment. Recent updates by ESMO/MASCC and ASCO on guidelines for prevention of CINV have recommended the addition of a neurokinin-1 receptor antagonist to antiemetic regimens for patients receiving carboplatin-based chemotherapy area under the curve (AUC) ≥4 mg/mL per minute, and an addition of olanzapine for those receiving combination anthracycline/cyclophosphamide chemotherapy.

Aims: To assess current use of prophylactic antiemetics and rates of CINV in patients under the care of MidCentral Regional Cancer Treatment Service (MRCTS) receiving carboplatin AUC≥4 or combination anthracycline/cyclophosphamide. Read More

View Article and Full-Text PDF

Management of Myositis-Associated Interstitial Lung Disease.

Medicina (Kaunas) 2021 Apr 3;57(4). Epub 2021 Apr 3.

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan.

Idiopathic inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM), are a diverse group of autoimmune diseases characterized by muscular involvement and extramuscular manifestations. Interstitial lung disease (ILD) has major pulmonary involvement and is associated with increased mortality in PM/DM/CADM. The management of PM-/DM-/CADM-associated ILD (PM/DM/CADM-ILD) requires careful evaluation of the disease severity and clinical subtype, including the ILD forms (acute/subacute or chronic), because of the substantial heterogeneity of their clinical courses. Read More

View Article and Full-Text PDF

Novel Therapies for ANCA-associated Vasculitis.

Curr Rheumatol Rep 2021 Apr 28;23(6):38. Epub 2021 Apr 28.

Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pz.le Golgi 2, 27100, Pavia, Italy.

Purpose Of Review: The purpose of this review is to discuss the most recent evidence on the treatment innovations and future prospective in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs).

Recent Findings: In AAV, a growing body of research is available on novel treatment options for remission induction and to clarify some uncertainties concerning the optimal use of available drugs. Efforts are being made to reduce the toxicity associated with high-dose, prolonged glucocorticoids (GC) regimens. Read More

View Article and Full-Text PDF

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

Autoimmun Rev 2021 Apr 19;20(6):102830. Epub 2021 Apr 19.

Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Av. de Valdecilla 25, 39008 Santander, Cantabria, Spain; University of Cantabria, Santander, Spain; University of Witwatersrand, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, South Africa. Electronic address:

Background: Interstitial lung disease (ILD) is a serious complication that represents the second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA-ILD remains controversial. The absence of randomized clinical trials and specific ACR or EULAR therapeutic guidelines makes it difficult to establish solid therapeutic recommendations on this issue. Read More

View Article and Full-Text PDF

Complementary Structural Information for Stressed Antibodies from Hydrogen-Deuterium Exchange and Covalent Labeling Mass Spectrometry.

J Am Soc Mass Spectrom 2021 May 22;32(5):1237-1248. Epub 2021 Apr 22.

Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States.

Identifying changes in the higher-order structure (HOS) of therapeutic monoclonal antibodies upon storage, stress, or mishandling is important for ensuring efficacy and avoiding adverse effects. Here, we demonstrate diethylpyrocarbonate (DEPC)-based covalent labeling (CL) mass spectrometry (MS) and hydrogen-deuterium exchange (HDX)/MS can be used together to provide site-specific information about subtle conformational changes that are undetectable by traditional techniques. Using heat-stressed rituximab as a model protein, we demonstrate that CL/MS is more sensitive than HDX/MS to subtle HOS structural changes under low stress conditions (e. Read More

View Article and Full-Text PDF

Primary Bone Lymphoma: A 13 Year Retrospective Institutional Analysis in the Chemo-Immunotherapy Era.

Indian J Hematol Blood Transfus 2021 Apr 8;37(2):240-248. Epub 2020 Aug 8.

Department of Hemato-Oncology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, New Delhi 110085 India.

Primary Lymphoma of bone (PBL) is an uncommon extranodal tumor accounting for 1% of all malignant lymphomas. The incidence of PBL is so rare that many of its aspects remain unknown. We retrospectively analysed our data in order to know clinical characteristics and treatment outcome in Indian population in chemo-immunotherapy era. Read More

View Article and Full-Text PDF

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Oncol 2021 05 10;22(5):678-689. Epub 2021 Apr 10.

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.

Background: Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to assess the efficacy and safety of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

Methods: CHRONOS-3 was a multicentre, double-blind, randomised, placebo-controlled, phase 3 study in 186 academic medical centres across Asia, Australia, Europe, New Zealand, North America, Russia, South Africa, and South America. Read More

View Article and Full-Text PDF

Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.

Int J Hematol 2021 Apr 13. Epub 2021 Apr 13.

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita City, Osaka, 565-0871, Japan.

High pre-treatment serum soluble interleukin-2 receptor (sIL-2R) levels are associated with poor overall survival (OS) of patients with newly diagnosed follicular lymphoma (FL). We evaluated the usefulness of pre-treatment sIL-2R levels in selecting a treatment regimen for advanced-stage FL with low tumor burden (FL-LTB). This retrospective, multicenter observational study enrolled consecutive patients who received a rituximab-containing regimen for newly diagnosed advanced stage FL-LTB (grade 1-3a) between 2008 and 2018. Read More

View Article and Full-Text PDF

Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis?

BMJ Case Rep 2021 Apr 12;14(4). Epub 2021 Apr 12.

Division of Rheumatology, Department of Medicine, UF Health Jacksonville, Jacksonville, Florida, USA.

We describe a case of a 48-year-old woman who presented with acute respiratory failure due to diffuse alveolar haemorrhage and acute renal failure due to pauci-immune glomerulonephritis consistent with a new diagnosis of microscopic polyangiitis (MPA). The patient had a recent SARS-CoV-2 infection 6 weeks before MPA diagnosis and had stopped immunosuppression for her rheumatoid arthritis (RA) at that time. The patient was treated with pulse intravenous steroids, plasma exchange therapy and rituximab, which induced remission of her illness. Read More

View Article and Full-Text PDF

[Methemoglobinemia caused by dapsone. Report of one case].

Rev Med Chil 2020 Dec;148(12):1838-1843

Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Methemoglobinemia is a rare condition with serious consequences if not diagnosed. We report the case of a 64-year-old woman with a history of allergy to sulfa drugs and a recent diagnosis of a small vessel vasculitis (ANCA-p) who started induction therapy with corticosteroids and rituximab. Due to the need for infectious prophylaxis, and considering her history, dapsone was administered instead of cotrimoxazole after ruling out glucose-6-phosphate dehydrogenase deficiency. Read More

View Article and Full-Text PDF
December 2020

Lupus Cerebritis Refractory to Guideline-Directed Therapy: A Case Report.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211008708

SUNY Upstate Medical University, Syracuse, NY, USA.

Systemic lupus erythematosus is an autoimmune disease that affects multiple organs and organ systems, subsequently requiring an elaborate regimen for management. We present the case of a 63-year-old female who developed unrelenting symptoms of drug-induced lupus, which persisted even after the offending agent was withdrawn, unmasking her underlying systemic lupus erythematosus. She continued to develop neuropsychiatric symptoms, including mania and hallucinations, which complicated the management of her disease. Read More

View Article and Full-Text PDF

Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report.

J Med Case Rep 2021 Apr 12;15(1):161. Epub 2021 Apr 12.

Department of Internal Medicine, AMITA Health Saint Francis Hospital, 355 Ridge Ave, Evanston, IL, 60202, USA.

Background: Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiologic entity characterized by headaches, altered mental status, seizures, visual loss, and a characteristic imaging pattern in brain magnetic resonance images. The exact etiology and pathogenesis of this condition are not yet fully elucidated.

Case Presentation: A 72-year-old White man presented with 2 weeks of low-grade fever and chills, night sweats, fatigue, dysphagia, and new-onset rapidly increasing cervical lymphadenopathy. Read More

View Article and Full-Text PDF

NHL Progression Risk Cut with Copanlisib-Rituximab Combo.


Cancer Discov 2021 Apr 10. Epub 2021 Apr 10.

According to results from the phase III CHRONOS-3 trial, patients with relapsed indolent non-Hodgkin lymphoma may benefit significantly from the addition of copanlisib, a pan-PI3K inhibitor, to standard rituximab. The combination was safe and nearly halved the risk of disease progression or death, compared with placebo and rituximab. Read More

View Article and Full-Text PDF

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.

Clin Cancer Res 2021 Apr 8. Epub 2021 Apr 8.

Washington University School of Medicine, St. Louis, Missouri.

Purpose: N-803 is an IL15 receptor superagonist complex, designed to optimize persistence and trans-presentation, thereby activating and expanding natural killer (NK) cells and CD8 T cells. Monoclonal antibodies (mAbs) direct Fc receptor-bearing immune cells, including NK cells, to recognize and eliminate cancer targets. The ability of IL15R agonists to enhance tumor-targeting mAbs in patients has not been reported previously. Read More

View Article and Full-Text PDF

Primary central nervous system vasculitis - An update on diagnosis, differential diagnosis and treatment.

J Neurol Sci 2021 May 27;424:117422. Epub 2021 Mar 27.

Department of Neurology, Alfried Krupp Hospital, Alfried-Krupp-Strasse 21, 45130 Essen, Germany; German Society of Neurology, Reinhardtstrasse 27 C, 10117 Berlin, Germany.

Importance: Primary angiitis of the central nervous system (PACNS) is a rare condition which is often misdiagnosed. In order to avoid mistakes in the management, a step by step approach is necessary.

Observations: The most common presenting symptoms of PACNS are encephalopathy-related cognitive and affective abnormalities, headaches and multifocal symptoms associated with recurrent episodes of ischemia or hemorrhage. Read More

View Article and Full-Text PDF

Therapy of ocular complications in ANCA+ associated vasculitis.

Rom J Ophthalmol 2021 Jan-Mar;65(1):10-14

Cluj County Emergency Hospital, Cluj-Napoca, Romania.

ANCA+ associated vasculitis (AAV) is a group of rare diseases with potentially vision-threatening complications. Ocular and orbital complications of these diseases are caused by vasculitis of the small vessels of the eye or by granulomatous mass formation. ANCA (anti-neutrophil cytoplasmic antibodies) represent a key component of pathophysiological pathways as well as a diagnostic marker. Read More

View Article and Full-Text PDF

When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.

Curr Hematol Malig Rep 2021 Feb 2;16(1):45-51. Epub 2021 Apr 2.

Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.

Purpose Of Review: Follicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era. Despite favorable responses and improving remission duration, FL remains largely incurable with patterns of relapsing and remitting disease with many patients requiring multiple lines of therapy. As our understanding of the malignant B-cell biology evolves, more targeted therapies have emerged for the treatment of follicular lymphoma. Read More

View Article and Full-Text PDF
February 2021

The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.

Ther Adv Hematol 2021 30;12:2040620721989588. Epub 2021 Jan 30.

City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA.

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relapsed/refractory setting and over chlorambucil in older patients with disease. The phase III ECOG-ACRIN trial extended these results to young, fit patients, demonstrating a significant survival advantage to ibrutinib plus rituximab over fludarabine, cyclophosphamide, and rituximab. Read More

View Article and Full-Text PDF
January 2021

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Ther Adv Hematol 2021 30;12:2040620721989579. Epub 2021 Jan 30.

Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerología México, Unit of Biomedical Research on Cancer, Mexico City, Mexico.

Background: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma worldwide. The current standard of care is chemoimmunotherapy with an R-CHOP regimen. We aim to review the role of this regimen after two decades of being the standard of care. Read More

View Article and Full-Text PDF
January 2021

Clinical experience with biologic treatment in resistant eosinophilic fasciitis: Case reports and review of the literature.

Medicine (Baltimore) 2021 Apr;100(13):e25359

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.

Rationale: Eosinophilic fasciitis (EF) is an uncommon connective tissue disorder characterized by limb and trunk erythema, with symmetrical thickening of the skin. Its pathogenesis is poorly understood. Treatment consists mainly of glucocorticoids. Read More

View Article and Full-Text PDF

Disease-modifying treatments for primary autoimmune haemolytic anaemia.

Cochrane Database Syst Rev 2021 03 26;3:CD012493. Epub 2021 Mar 26.

Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Background: Primary autoimmune haemolytic anaemia (AIHA) is an autoantibody mediated condition characterised by a variable disease course. A myriad of immunomodulatory agents have been employed but there is a paucity of evidence to support their use or compare their effectiveness.

Objectives: To determine the effects of various disease-modifying treatment modalities in people with AHIHA. Read More

View Article and Full-Text PDF

Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.

Ther Adv Neurol Disord 2021 12;14:1756286421998918. Epub 2021 Mar 12.

Department of Rheumatology and Immunology, Nanchong Central Hospital, Nanchong, Sichuan, China.

Immune-mediated necrotizing myopathy (IMNM) is a group of immune-related myopathies characterized by progressive proximal muscle weakness, extremely high serum creatine kinase (CK) levels, and necrotic muscle fibers with a relative lack of inflammation. Treatment of IMNM is challenging, with most cases refractory to high-dose steroids in combination with multiple immunotherapies. The role of rituximab (RTX) for IMNM has been explored in isolated case reports and small series. Read More

View Article and Full-Text PDF

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Clin Cancer Res 2021 Mar 30. Epub 2021 Mar 30.

Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.

Background: The nuclear exporter protein exportin-1 (XPO1) is overexpressed in non-Hodgkin lymphoma (NHL) and correlates with poor prognosis. We evaluated enhancing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) activity in NHL by targeted inhibition of XPO1 using the selective inhibitor of nuclear export (SINE) compounds.

Methods: We evaluated the antitumor activity of SINE compounds in combination with CHO chemotherapy and . Read More

View Article and Full-Text PDF

Rituximab for refractory primary angiitis of the central nervous system: Experience in two patients.

Mult Scler Relat Disord 2021 Mar 18;51:102907. Epub 2021 Mar 18.

Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India. Electronic address:

Primary Angiitis of the Central Nervous System (PACNS) is an aggressive disease with a high rate of relapse and mortality. Majority of patients attains clinical remission with a combination of glucocorticoids and cyclophosphamide. However, there is limited evidence on further management in patients who relapse or does not achieve clinical improvement while on first line treatment. Read More

View Article and Full-Text PDF